
Melanoma Vaccine Cuts Cancer Return Risk by 42%
A personalized melanoma vaccine combined with standard treatment reduces the risk of cancer returning by 42%, marking the first successful clinical trial for personalized mRNA cancer vaccines. The breakthrough could pave the way for similar vaccines to treat other cancers.
%3Amax_bytes(150000)%3Astrip_icc()%3Afocal(749x0%3A751x2)%2FKelly-Spill-101826-1-388f1215e2364e97b42034e8d47a0c9e.jpg)





